| Population name | Speletas |
| Genome | not specified |
| Consortium | Universities and hospitals in Greece |
| Super population | EUR, EAS |
| Population description | Participants were enrolled in the study from March to October 2020. The ethnicity of patients included 152 Greeks, 62 Turks, 16 Ukrainians, 15 Indonesians, 6 Uzbeks, 3 Moldovans, 3 Americans, 2 Cubans and 1 patient from each of the following countries: Albania, Belarus, Bulgaria, Germany, and Kyrgyzstan. Most patients of non-Greek origin were passengers and crew members on a cruise ferry who became infected with COVID-19 in March 2020. |
| Population origin | Greece |
| Case population size | 264 |
| Control population size | none |
| Comorbidities | 35.6% with one or more comorbidities including obesity, hypertension, chronic heart disease, chronic rspiratory disease, dyslipidemia, diabetes, hypothyrodism, malignancies, live/renal/hematological disease |
| Mean / median age | 42.8 ± 18.4 years |
| Sex | 180 male; 84 female |
| Severity | Severe |
| Sample source | TBD |
| Method | DNA was extracted from peripheral blood, with the detection of MBL2 genetic alterations performed by allele-specific polymerase chain reaction, followed by restriction fragment length polymorphism (PCR-RFLP) analysis |
| Bioinformatics | Multivariate analysis was performed in the form of binary logistic regression for all parameters, with a statistical significance of p > 0.2 in univariate analysis. For all the analyses, a 5% significance level was set. Analysis was carried out with SPSS (version 25.0). |
| Imputation details | NA |
| Limitations | a. No association of the known MBL genetic deficiency to COVID-19 severity but only of the B allele (rs1800450) itself. This could indicate that the results may be affected by the small sample size , diverse composition of the cohort analysed, confounding factors such as smoking, diet and oxidative stress levels that affect MBL serum levels |